The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
The Role Of The Transcription Factor Blimp-1 In Tumour Immunity
Funder
National Health and Medical Research Council
Funding Amount
$642,674.00
Summary
Regulatory T (Treg) cells function by suppressing immune system activity, ensuring that our immune system does not mount a response against our own tissue. In cancer, Treg cells suppress anti-tumour immunity, facilitating tumour growth. Recently we have identified a group of active Treg cells that may be the key drivers of immune response regulation. Our work will examine the role of these active Treg cells in tumour immunity, opening the door to more effective targeting of Treg cells in cancer.
Strategies To Enhance CD4 T Cell-mediated Anti-tumour Immunity
Funder
National Health and Medical Research Council
Funding Amount
$529,577.00
Summary
The immune system is capable of controlling cancer, but frequently does not do so. In this project we will study two factors that compromise anti-cancer immune responses: regulatory T cells, which suppress immune responses, and tolerogenic dendritic cells, which subvert potentially beneficial responses to tumours. By manipulating these factors, we hope to enhance the effectiveness of the immune response against cancer.
Analysis Of Killer T Cell Geometry During An Anti-tumour Response
Funder
National Health and Medical Research Council
Funding Amount
$547,216.00
Summary
Cancer is a major health problem around the world. Currently used treatment options of cancer have the drawback that they also damage healthy tissues. This limits the dosages that can be administered, frequently resulting in treatment failure. Anti-tumour killer T cells are a naturally occurring cell type that can cause tumour regression. In the present proposal, we explore how the efficiency of these cell-types can be further enhanced to induce rejection of progressing tumours.
Development Of CD96 Antibodies For Cancer Treatment
Funder
National Health and Medical Research Council
Funding Amount
$820,821.00
Summary
There is an unmet medical need to develop new immunotherapies that are safer and potentially allow the treatment of a broader range of cancers. Inhibiting the immune checkpoint CD96 function represents an opportunity that may parallel and indeed complement the activity and impact of other lymphocyte checkpoint inhibitors in human cancer (eg. CTLA-4 and PD1/PD-L1). While developing a new human therapeutic antibody we will also learn more about an important checkpoint in the immune response.
The Role Of The Actomyosin Cytoskeleton In T Cell-mediated Anti-tumour Immunity
Funder
National Health and Medical Research Council
Funding Amount
$616,950.00
Summary
T cells, specialised immune cells, are crucial in the defence against tumours. In order to reach cancerous target cells, T cells must enter tumour tissues from the blood stream and then effectively migrate in the extravascular space. This application aims to uncover the role of the cytoskeleton, a group of molecules driving cell shape change and motility, in the efficient execution of T cell anti-tumour function. These studies will aid the development of improved immunotherapies against cancer.
Investigating The Anti-tumour Efficacy And On Target Toxicity Of Gene-modified T Cell Therapy In Vivo
Funder
National Health and Medical Research Council
Funding Amount
$337,614.00
Summary
White blood cells from cancer patients can be modified in the laboratory to react against tumours. Although these cells can induce cancer regression when given back to the patient, these cells can often cause associated pathology. In this study we propose to fully investigate the limits of this type of therapy for mediating anti-tumour responses and potential toxicity in mouse models that closely recapitulate the human setting. These studies will lead to a more effective therapy for patients.
The Role Of NK Cell Receptors In Tumor Immunity And Cancer Therapy
Funder
National Health and Medical Research Council
Funding Amount
$641,264.00
Summary
White blood cells lymphocytes have an important role to play in cancer immunity and the activity of some cancer therapies. Therapeutics that improve lymphocyte function in patient tumors are showing great promise. Yet, virtually nothing is known about one family of lymphocyte receptors that control function in cancer. Using relevant mouse models of cancer and patient tumors we now wish to assess the relative importance of this family of receptors in tumor immunity, therapy, and escape.